Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | STK10 | O94804 | 1/20 | 0.36 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372119 | 0.79 | KMT2A (0.53) | KMT2AALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL9023146 | 0.79 | ALDH1A1 (0.54) | KMT2AALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL374339 | 0.77 | ALDH1A1 (0.67) | KMT2AALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL372120 | 0.72 | KMT2A (0.54) | KMT2AALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL9022802 | 0.70 | ALDH1A1 (0.52) | KMT2AALDH1A1HSD17B10MAPK1GAA | |
| SCHEMBL15254279 | 0.69 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CASP1CASP7TSHR | |
| SCHEMBL371969 | 0.69 | KMT2A (0.50) | KMT2AALDH1A1HSD17B10MAPK1KDM4E | |
| SCHEMBL372408 | 0.69 | KMT2A (0.50) | KMT2AALDH1A1HSD17B10MAPK1KDM4E | |
| SCHEMBL5649656 | 0.69 | ALDH1A1 (0.56) | KMT2AALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL9197946 | 0.69 | KMT2A (1.00) | KMT2AALDH1A1HSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2213661-A1 | c-Met Modulators and Methods of Use | Exelixis Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KMT2A 977/4885ALDH1A1 2072/4885HSD17B10 4532/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | KMT2A 977/4885ALDH1A1 2072/4885HSD17B10 4532/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KMT2A 977/4885ALDH1A1 2072/4885HSD17B10 4532/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KMT2A 977/4885ALDH1A1 2072/4885HSD17B10 4532/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | KMT2A 977/4885ALDH1A1 2072/4885HSD17B10 4532/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | KMT2A 1800/4885ALDH1A1 2327/4885HSD17B10 4435/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | KMT2A 732/4885ALDH1A1 2597/4885HSD17B10 4611/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | KMT2A 769/4885ALDH1A1 2578/4885HSD17B10 4608/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | KMT2A 769/4885ALDH1A1 2578/4885HSD17B10 4608/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | KMT2A 769/4885ALDH1A1 2578/4885HSD17B10 4608/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | KMT2A 977/4885ALDH1A1 2072/4885HSD17B10 4532/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | KMT2A 732/4885ALDH1A1 2597/4885HSD17B10 4611/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | KMT2A 769/4885ALDH1A1 2578/4885HSD17B10 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.